Rhelion says Filament Health wins new US patent for controlled extraction of psychoactive alkaloids

Reuters2026/08/27 12:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rhelion Life Sciences reported a new U.S. patent issued to its Filament Health unit for “Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids.”
The patent expands the intellectual property backing PEX010, its GMP botanical psilocybin drug candidate used in more than 80 studies.
Rhelion said Filament’s portfolio now totals 77 issued patents across 13 patent families following the grant.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608270824NEWSFILECNPR____20260827_311795_1) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rhelion says Filament Health wins new US patent for controlled extraction of psychoactive alkaloids

You may also like

Crypto prices